{
  "id": 16204517,
  "title": "Aim ImmunoTech CEO Equels buys $5,093 of common stock",
  "url": "https://urgent.news/2026/10/23/aim-immunotech-ceo-equels-buys-5-093-of-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T17:01:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/aim-immunotech-ceo-equels-buys-5093-of-common-stock-93CH-4970157"
  },
  "original_language": "en",
  "account": "AIM ImmunoTech Inc. (AIM) CEO and President Thomas K. Equels acquired 31,250 shares of the company's common stock on October 22, 2026, at a price of $0.163 per share. The total cost of this purchase was $5,093. The stock traded near its 52-week low of $0.16, with a 94% decline over the past year. After this transaction, Mr. Equels now owns 158,072 shares of AIM's common stock and also serves as a Director. InvestingPro analysis suggests the stock is currently undervalued, given its strong balance sheet with more cash than debt. AIM ImmunoTech has also entered into a $1.5 million manufacturing agreement with Sterling Pharma Solutions. The agreement, effective July 31, 2026, will see AIM receiving additional batches of polynucleotide drug substances PolyI and Poly C12U at Sterling's facility in Dudley, UK. These substances are crucial for AIM's drug product, Ampligen, and will be produced over a 12-month period. Thomas K. Equels, in an article for Breaking Defense, discusses the potential of Ampligen as a broad-spectrum antiviral therapeutic, focusing on its possible use in treating Ebola virus disease and COVID-19. However, the article's preclinical findings do not guarantee FDA approval or clinical efficacy. AIM ImmunoTech has provided an exhibit containing this forward-looking statement to the SEC.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}